Literature DB >> 12171772

Circulating thrombopoietin in clonal versus reactive thrombocytosis.

Sema Karakuş1, Osman I Ozcebe, Ibrahim C Haznedaroğlu, Hakan Göker, Düzgün Ozatli, Ali Koşar, Yahya BüyükaşIk, Derun Ertuğrul, Nilgün SayInalp, Serafettin KirazlI, Semra V Dündar.   

Abstract

INTRODUCTION: The aim of this study is to assess circulating thrombopoietin concentrations in patients with both clonal and reactive thrombocytosis (RT), which are two distinct categories of extreme platelet production circumstances. Investigation of the thrombopoietin levels in clonal versus reactive thrombocytosis may help us to understand the interactions of this key regulatory cytokine and the conditions in which abnormally increased platelet formation exist.
MATERIALS AND METHODS: Thrombopoietin levels were measured in patients with platelet counts greater than 500 x1 0(3) microl(-1). The study population consisted of 21 patients with RT (13 with iron deficiency anemia, and 8 with rheumatoid arthritis), 24 patients with clonal thrombocytosis (six with essential thrombocytosis, three with myelofibrosis, eight with chronic myelogenous leukemia, and seven with polycythemia vera (PV)) and 16 healthy subjects were used as controls.
RESULTS: The median plasma thrombopoietin concentration was 100.5 pg ml(-1) in patients with RT, 467 pg ml(-1) in patients with clonal thrombocytosis and 62.65 pg ml(-1) in the control group. The thrombopoietin concentration was found to be higher in the patients with primary thrombocytosis when compared to the control group (p=0.001), as well as in patients with RT (p=0.002). However, there was no statistically significant difference between the patients with RT and the control group (p=0.14). There was no correlation between thrombopoietin levels and the platelet counts in patients with clonal thrombocytosis, including essential thrombocythemia (ET). CONCLUSIION: Increased levels of thrombopoietin were found in patients with clonal thrombocytosis versus patients with RT and control subjects as well. Defective clearance of thrombopoietin by megakaryocytes and platelets due to a reduced number of thrombopoietin receptors may be the causative mechanism behind this. These results indicate that plasma thrombopoietin levels may be helpful in distinguishing between clonal and reactive thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171772     DOI: 10.1080/10245330290020081

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  6 in total

1.  Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.

Authors:  Nya D Nelson; Andrea Marcogliese; Katie Bergstrom; Michael Scheurer; Donald Mahoney; Alison A Bertuch
Journal:  Pediatr Blood Cancer       Date:  2016-04-21       Impact factor: 3.167

Review 2.  Pathologic thrombopoiesis of rheumatoid arthritis.

Authors:  Ihsan Ertenli; Sedat Kiraz; M Akif Oztürk; Ibrahim c Haznedaroğlu; Ismail Celik; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-02-11       Impact factor: 2.631

3.  Designing a Scoring System for Differential Diagnosis From Reactive Thrombocytosis and Essential Thrombocytosis.

Authors:  Chih-Lung Shen; Tsung-Cheng Hsieh; Tso-Fu Wang; Wei-Han Huang; Sung-Chao Chu; Yi-Feng Wu
Journal:  Front Med (Lausanne)       Date:  2021-12-16

4.  TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.

Authors:  Jan Palmblad; Magnus Björkholm; Jack Kutti; Gerd Lärfars; Eva Löfvenberg; Berit Markevärn; Mats Merup; Nils Mauritzson; Jan Westin; Jan Samuelsson; Gunnar Birgegård
Journal:  Int J Med Sci       Date:  2008-04-13       Impact factor: 3.738

Review 5.  Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest.

Authors:  Julie Mondet; Kais Hussein; Pascal Mossuz
Journal:  Mediators Inflamm       Date:  2015-10-07       Impact factor: 4.711

6.  Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors.

Authors:  Zhihe Liu; Hongqiong Fan; Yuying Li; Chunshui Liu
Journal:  Onco Targets Ther       Date:  2017-07-17       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.